Targeted cancer therapy: Conferring specificity to cytotoxic drugs

Accounts of Chemical Research

Volumn 41, Issue 1, 2008, Pages 98-107

  Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOTOXIN; MAYTANSINE; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; HUMAN; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG DESIGN; HUMANS; IMMUNOTOXINS; MAYTANSINE; MOLECULAR STRUCTURE; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38949192547     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar700108g     Document Type: Article

References (36)

1. Frei, E.; Elias, A.; Wheeler, C.; Richardson, P.; Hryniuk, W. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin. Cancer Res. 1998, 4, 2027-2037.
2. Chari, R. V. J. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Adv. Drug Delivery Rev. 1998, 31, 89-104.
3. Uadia, P.; Blair, A. H.; Ghose, T. Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. Cancer Res. 1984, 44, 4263-4266.
4. Laguzza, B. C.; Nichols, C. L.; Briggs, S. L.; Cullinan, G. J.; Johnson, D. A.; Starling, J. J.; Baker, A. L.; Bumol, T. F.; Corvalan, J. R. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. J. Med. Chem. 1989, 32, 548-555.
5. Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261, 212-215.
6. Elias, D. J.; Hirschowitz, L.; Kline, L. E.; Kroener, J. F.; Dillman, R. O.; Walker, L. E.; Robb, J. A.; Timms, R. M. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 1990, 50, 4154-4159.
7. Ajani, J. A.; Kelsen, D. P.; Haller, D. A. Multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000, 6, 78-81.
8. Tolcher, A. W.; Sugarman, S.; Gelman, K. A.; Cohen, R.; Saleh, M.; Isaacs, C.; Young, L.; Healey, D.; Onetto, N.; Slichenmeyer, W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17, 478-484.
9. Sedlacek, H.-H.; Seemann, G.; Hoffmann, D.; Czech, J.; Lorenz, P.; Kolar, C.; Bosslet, K. Antibodies as carriers of cytotoxicity. Contributions to Oncology; Karger: Basel, Switzerland, 1992; pp 1-145.
10. Meister, A.; Anderson, M. E. Glutathione. Ann. Rev. Biochem. 1983, 52, 711-760.
11. Kupchan, S. M.; Komoda, Y.; Branfman, A. R.; Sneden, A. T.; Court, W. A.; Thomas, G. J.; Hintz, H. P.; Smith, R. M.; Karim, A.; Howie, G. A.; Verma, A. K.; Nagao, Y.; Dailey, R. G., Jr.; Zimmerly, V. A.; Sumner, W. C., Jr. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J. Org. Chem. 1977, 42, 2349-2357.
12. Issell, B. F.; Crooke, S. T. Maytansine. Cancer Treat. Rev. 1978, 5, 199-207.
13. Chari, R. V. J.; Martell, B. A.; Gross, J. L.; Cook, S. B.; Shah, S. A.; Blättler, W. A.; McKenzie, S. J.; Goldmacher, V. S. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res. 1992, 52, 127-131.
14. Widdison, W. C.; Wilhelm, S. D.; Cavanagh, E. E.; Whiteman, K. R.; Leece, B. A.; Kovtun, Y.; Goldmacher, V. S.; Xie, H.; Steeves, R. M.; Lutz, R. J.; Zhao, R.; Wang, L.; Blättler, W. A.; Chari, R. V. J, Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392-4408.
15. Erickson, H. K.; Park, P. U.; Widdison, W. C.; Kovtun, Y. V.; Garrett, L. M.; Hoffman, K.; Lutz, R. J.; Goldmacher, V. S.; Blättler, W. A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006, 66, 4426-4433.
16. Kovtun, Y. V.; Audette, C. A.; Ye, Y.; Xie, H.; Ruberti, M. F.; Phinney, S. J.; Leece, B. A.; Chittenden, T.; Blättler, W. A.; Goldmacher, V. S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006, 66, 3214-3221.
17. Xie, H.; Audette, C.; Hoffee, M.; Lambert, J. M.; Blättler, W. A. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 2004, 310, 1073-1082.
18. Liu, C.; Tadayoni, B. M.; Bourret, L. A.; Mattocks, K. M.; Derr, S. M.; Widdison, W. C.; Kedersha, N. L.; Ariniello, P. D.; Goldmacher, V. S.; Lambert, J. M.; Blättler, W. A.; Chari, R. V. J. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8618-8623.
19. + multiple myeloma cells. Cancer Res. 2004, 64, 4629-4636.
20. Henry, M. D.; Wen, S.; Silva, M. D.; Chandra, S.; Milton, M.; Worland, P. J. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004, 64, 7995-8001.
21. Ranson, M.; Slikowski, M. X. Perspectives on anti-HER2 monoclonal antibodies. Oncology 2002, 63 (supplement 1), 17-24.
22. Tolcher, A. W.; Ochoa, L.; Hammond, L. A.; Patnaik, A.; Edwards, T.; Takimoto, C.; Smith, L.; de Bono, J.; Schwartz, G.; Mays, T.; Jonak, Z. L.; Johnson, R.; DeWitte, M.; Martino, H.; Audette, C.; Maes, K.; Chari, R. V. J.; Lambert, J. M.; Rowinsky, E. K. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 2003, 21, 211-222.
23. Reynolds, V. L.; McGovren, J. P.; Hurley, L. H. The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic. J. Antibiot. 1986, 39, 319-334.
24. Cristofanilli, M.; Bryan, W. J.; Miller, L. L.; Chang, A.Y.; Gradishar, W. J.; Kufe, D. W.; Hortobagyi, G. N. Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs 1998, 9, 779-782.
25. Chari, R. V. J.; Jackel, K. A.; Bourret, L. A.; Derr, S. M.; Tadayoni, B. M.; Mattocks, K. M.; Shah, S. A.; Liu, C.; Blättler, W. A.; Goldmacher, V. S. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analog through immunoconjugate formation. Cancer Res. 1995, 55, 4079-4084.
26. Kaul, S.; Igwemezie, L. N.; Stewart, D. J.; Fields, S. Z.; Kosty, M.; Levithan, N.; Bukowski, R.; Gandara, D.; Goss, G.; O'Dwyer, P. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J. Clin. Oncol. 1995, 13, 2835-2841.
27. Miller, M. L.; Roller, E. E.; Wu, X.; Leece, B. A.; Goldmacher, V. S.; Chari, R. V. J.; Ojima, I. Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies. Bioorg. Med. Chem. Lett. 2004, 14, 4079-4082.
28. Miller, M. L.; Roller, E. E.; Zhao, R. Y.; Leece, B. A.; Ab, O.; Baloglu, E.; Goldmacher, V. S.; Chari, R. V. J. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery. J. Med. Chem. 2004, 47, 4802-4805.
29. Baloglu, E.; Miller, M. L.; Roller, E. E.; Cavanagh, E. E.; Leece, B. A.; Goldmacher, V. S.; Chari, R. V. J. Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors. Bioorg. Med. Chem. Lett. 2004, 14, 5885-5888.
30. Ojima, I.; Geng, X.; Wu, X.; Qu, C.; Borella, C. P.; Xie, H.; Wilhelm, S. D.; Leece, B. A.; Bartle, L. M.; Goldmacher, V. S.; Chari, R. V. J. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 2002, 45, 5620-5623.
31. Hamann, P. R.; Hinman, L. M.; Hollander, I.; Beyer, C. F.; Lindh, D.; Holcomb, R.; Hallett, W.; Tsou, H. R.; Upeslacis, J.; Shochat, D.; Mountain, A.; Flowers, D. A.; Bernstein, I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 2002, 13, 47-58.
32. Bross, P. F.; Beitz, J.; Chen, G.; Chen, X. H.; Duffy, E.; Kieffer, L.; Roy, S.; Sridhara, R.; Rahman, A.; Williams, G.; Pazdur, R. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 1490-1496.
33. DiJoseph, J. F.; Armellino, D. C.; Boghaert, E. R.; Khandke, K.; Dougher, M. M.; Sridharan, L.; Kunz, A.; Hamann, P. R.; Gorovits, B.; Udata, C.; Moran, J. K.; Popplewell, A. G.; Stephens, S.; Frost, P.; Damle, N. K. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004, 103, 1807-1814.
34. Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinma, A. A.; Boettner, F. E.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems, R. J. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J. Am. Chem. Soc. 1987, 109, 6883-6885.
35. Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; Francisco, J. A.; Wahl, A. F.; Meyer, D. L.; Senter, P. D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol 2003, 21, 778-784.
36. Doronina, S. O.; Mendelsohn, B. A.; Bovee, T. D.; Cerveny, C. G.; Alley, S. C.; Meyer, D. L.; Oflazoglu, E.; Toki, B. E.; Sanderson, R. J.; Zabinski, R. F.; Wahl, A. F.; Senter, P. D. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 2006, 17, 114-124.